$ARCT
Arcturus Therapeutics Holdings Inc
PRICE
$18.34 โผ-3.175%
Last Close
VOLUME
715,529
DAY RANGE
18.02 - 19.59
52 WEEK
11.7 - 65
Join Discuss about ARCT with like-minded investors
@marketjay #marketassasins
**1) ARCT** 2021 has not been kind to ARCT. As this is now near the levels of the beginning of the year after falling back on 12/28/20. Recent momentum and liquidity creeping in is indicating a possible run into 2022. Watch for the break over $47 for an opportunity to swing for calls to the $54 level which served as 12/29/20 gap down starting point. This is a small resistance as a break over $54 PT should be re adjusted to PT 1: $57, PT 2: $60, PT 3: $63. January contracts last available strike are the $55 with heavy open interest, contracts will be costly but present a risk vs reward of 1/3
85 Replies 11 ๐ 9 ๐ฅ
@CarlosH-carvan #ivtrades
Cathie Wood's ARK Invest Posts Fund Purchases For Monday, Nov. 1, 2021: NTLA, BEAM, PATH, KTOS, VLD, NIU, BLDE, MKFG, ZM, GENI, EXAS, CDNA, ALLO, VERV, ARCT, ADPT, TWLO, HOOD, TOST
145 Replies 7 ๐ 12 ๐ฅ
Key Metrics
Market Cap
483.47 M
Beta
0
Avg. Volume
861.02 K
Shares Outstanding
26.42 M
Yield
0%
Public Float
0
Next Earnings Date
2022-08-08
Next Dividend Date
Company Information
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. is a clinical-stage mRNA medicines and vaccines company with enabling technologies: (i) LUNARยฎ lipid-mediated delivery, (ii) STARRโข mRNA Technology and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus' diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat Ornithine Transcarbamylase (OTC) Deficiency, and Cystic Fibrosis along with partnered programs including Glycogen Storage Disease Type 3, Hepatitis B Virus, and non-alcoholic steatohepatitis (NASH). Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, replicon RNA, antisense RNA, microRNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (209 patents and patent applications, issued in the U.S., Europe, Japan, China and other countries). Arcturus' commitment to the development of novel RNA therapeutics has led to collaborations with Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, Ultragenyx Pharmaceutical, Inc., Takeda Pharmaceutical Company Limited, CureVac AG, Synthetic Genomics Inc., Duke-NUS Medical School, and the Cystic Fibrosis Foundation.
Website: arcturusrx.com
HQ: ,
Related News